Lantus, a long-acting insulin glargine, offers stable 24-hour blood sugar control for people with type 1 and type 2 diabetes. It is often introduced when other treatments are insufficient, and can be ...

More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has ...

Initiators of biosimilar insulin glargine-yfgn were more likely to reside in rural areas, live in long-term care facilities, or have multiple prescribers and were less likely to have previously used ...

Credit: Lannett. The approval was based on a comprehensive clinical program that included a phase 1 study comparing insulin glargine-aldy with insulin glargine in healthy male adults. Langlara is ...

The interchangeable biosimilar insulin glargine is approved for U.S. distribution through a newly established subsidiary, Lanexa Biologics. Tang added, “We are incredibly proud of what this ...

China's Sunshine Lake Pharma has won US Food and Drug Administration approval for its insulin glargine injection, marking the first time a Chinese-developed insulin has obtained the regulator's ...

Langlara is supplied as a 3mL single-patient-use prefilled pen. The Food and Drug Administration (FDA) has approved Langlara ™ (insulin glargine-aldy), an interchangeable biosimilar to Lantus ® ...